Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Toward in Vitro Production of Platelet From Induced Pluripotent Stem Cells Publisher Pubmed



Izady E1 ; Saltanatpour Z1, 2 ; Liu LP3 ; Alizadeh A4 ; Hamidieh AA1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Stem Cell and Regenerative Medicine Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Institute of Regenerative Medicine, Affiliated Hospital of Jiangsu University, Jiangsu University, Jiangsu, Zhenjiang, 212001, China
  4. 4. Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran

Source: Stem Cell Reviews and Reports Published:2022


Abstract

Platelets (PLTs) are small anucleate blood cells that release from polyploidy megakaryocytes(MKs). PLT transfusion is standard therapy to prevent hemorrhage. PLT transfusion is donor‐dependent way which have limitations including the inadequate donor blood supply, poor quality, and issues related to infection and immunity. Overcoming these obstacles is possible with in vitro production of human PLTs. Currently several cells have been considered as source to in vitro production of PLTs such as hematopoietic stem cells (HSCs), embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). However, HSCs are a limited source for PLT production and large-scale expansion of HSC-derived PLT remains difficult. Alternative sources can be ESCs which have unlimited expansion capacity. But ESCs have ethical issues related to destroying human embryos. iPSCs are considered as an ideal unlimited source for PLT production. They are able to differentiate into any cells and have the capacity of self-renewal. Moreover, iPSCs can be acquired from any donor and easily manipulated. Due to new advances in development of MK cell lines, bioreactors, feeder cell-free production and the ability of large scale generation, iPSC-based PLTs are moving toward clinical applicability and considering the minimal risk of alloimmunization and tumorigenesis of these products, there is great hopefulness they will become the standard source for blood transfusions in the future. This review will focus on how to progress of in vitro generation of PLT from stem cell especially iPSCs and some of the successful strategies that can be easily used in clinic will be described. Graphical Abstract: [Figure not available: see fulltext.] © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Other Related Docs
12. Stem Cell Therapies for Congenital Heart Disease, Biomedicine and Pharmacotherapy (2016)
20. Stem Cells and Heart Tissue Regeneration, Nanomedicine for Ischemic Cardiomyopathy: Progress# Opportunities# and Challenges (2020)
21. Engineering the Niche for Hair Regeneration — a Critical Review, Nanomedicine: Nanotechnology# Biology# and Medicine (2019)
25. Application of Nanomaterials in Three-Dimensional Stem Cell Culture, Journal of Cellular Biochemistry (2019)
30. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment, Regenerative Engineering and Translational Medicine (2024)
33. Stem Cell-Based Approach for the Treatment of Parkinson's Disease, Medical Journal of the Islamic Republic of Iran (2015)